Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Oropharyngeal cancer (tonsil and base of tongue), drawn from the whole corpus: 13 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
How far treatment can be reduced in HPV-positive disease without losing cures.
HPV-negative oropharyngeal cancer still has poor outcomes.
Long-term swallowing and dry mouth after chemoradiation.
HPV vaccination uptake in boys and in low-income countries.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 14 changes by month →When this page itself was last checked or edited.
HN005: de-escalated arms had worse PFS; control 2-year PFS 98%.
Two-year progression-free survival 96.
Severe toxicity similar; 2-year overall survival 97.
OS 14.
Swallowing quality of life at one year was statistically but not clinically meaningfully better after radiotherapy than after transoral robotic surgery; oncological outcomes were similar.